Literature DB >> 17132382

The effectiveness of a treatment protocol for male lower urinary tract symptoms in general practice: a practical randomised controlled trial.

Roelf J C Norg1, Kees van de Beek, Piet J M Portegijs, C P Onno van Schayck, J André Knottnerus.   

Abstract

BACKGROUND: Randomised controlled trials have shown the efficacy of several treatment modalities for lower urinary tract symptoms (LUTS) in selected populations. The effectiveness in daily practice has hardly been investigated, especially in primary care and is dependent on choices between all possible treatment options and best investigated in a comprehensive study, including all treatment modalities (watchful waiting, alpha-blockers, 5-alpha-reductase inhibitors, and surgery). AIM: Assessment of the effectiveness of a comprehensive treatment protocol for LUTS in primary care. DESIGN OF STUDY: Randomised controlled trial.
SETTING: Fourteen general practices in the Netherlands. INTERVENTION: treatment protocol based on a formalised expert opinion. Control condition: usual care. STUDY POPULATION: 208 subjects with moderate to severe LUTS (IPSS > or =8, median = 13). OUTCOME MEASURES: symptom severity (IPSS [International Prostate Symptom Score]), bother score (Dan-PSS [Danish Prostate Symptom Score]), and maximum urinary flow (Q(max)); incidence of acute urinary retention and urinary tract infections.
RESULTS: In the intervention group markedly more subjects used an alpha-blocker at end of follow-up than in the usual care group (24% versus 6%). No significant differences were found between intervention and control group in IPSS, Q(max) or Dan-PSS.
CONCLUSION: alpha-blockers and watchful waiting are the most frequent treatment modalities for LUTS in primary care. Our study showed no evidence that a protocol using well-defined indications for all possible treatment modalities based on a formalised expert opinion procedure has added value. Based on our results, we cannot recommend a broadening of the indication for alpha-blockers, which, however, seems to be the current trend.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132382      PMCID: PMC1934054     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  25 in total

1.  The appropriateness of treatment of benign prostatic hyperplasia: a comparison of Dutch and multinational criteria.

Authors:  J McDonnell; H J Stoevelaar; J L Bosch; J P Kahan
Journal:  Health Policy       Date:  2001-07       Impact factor: 2.980

2.  AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.

Authors: 
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

3.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors:  Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

4.  BHP Disease Management. Introduction and concluding remarks.

Authors:  C R Chapple
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

5.  Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group.

Authors:  P Abrams; W Schäfer; T L Tammela; D M Barrett; H Hedlund; H J Rollema; A Matos-Ferreira; J Nordling; R Bruskewitz; J T Andersen; T Hald; P Miller; R Kirby; S Mustonen; A Cannon; C A Jacobsen; G J Gormley; M P Malice; M A Bach
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

6.  Who should be treated and how? Evidence-based medicine in symptomatic BPH.

Authors:  M J Speakman
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

7.  Management of symptomatic BPH in the UK: who is treated and how?

Authors:  T A McNicholas
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

Review 8.  Tamsulosin for benign prostatic hyperplasia.

Authors:  T J Wilt; R Mac Donald; I Rutks
Journal:  Cochrane Database Syst Rev       Date:  2003

9.  Lower urinary tract symptoms of men seeking medical care--comparison of symptoms found in the clinical setting and in a community study.

Authors:  Naoya Masumori; Yoshinori Tanaka; Atsushi Takahashi; Naoki Itoh; Hiroshi Ogura; Seiji Furuya; Taiji Tsukamoto
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

Review 10.  Terazosin for benign prostatic hyperplasia.

Authors:  T J Wilt; R W Howe; I R Rutks; R MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2002
View more
  1 in total

1.  How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials.

Authors:  Antonia F H Smelt; Gerda M van der Weele; Jeanet W Blom; Jacobijn Gussekloo; Willem J J Assendelft
Journal:  Br J Gen Pract       Date:  2010-07       Impact factor: 5.386

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.